Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
14714 | 685 | 48.8 | 95% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
313 | 17635 | X LINKED AGAMMAGLOBULINEMIA//BRUTONS TYROSINE KINASE//BTK |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CBL B | Author keyword | 40 | 70% | 5% | 33 |
2 | CBL | Author keyword | 34 | 35% | 12% | 80 |
3 | CIN85 | Author keyword | 25 | 71% | 3% | 20 |
4 | C CBL | Author keyword | 20 | 39% | 6% | 41 |
5 | NEIL BOGART MEM S | Address | 7 | 67% | 1% | 6 |
6 | SLAP 2 | Author keyword | 6 | 80% | 1% | 4 |
7 | CBL PROTEINS | Author keyword | 6 | 71% | 1% | 5 |
8 | CBL FAMILY | Author keyword | 6 | 100% | 1% | 4 |
9 | TULA | Author keyword | 5 | 63% | 1% | 5 |
10 | BACTERIAL INFECT IMMUN | Address | 4 | 67% | 1% | 4 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CBL B | 40 | 70% | 5% | 33 | Search CBL+B | Search CBL+B |
2 | CBL | 34 | 35% | 12% | 80 | Search CBL | Search CBL |
3 | CIN85 | 25 | 71% | 3% | 20 | Search CIN85 | Search CIN85 |
4 | C CBL | 20 | 39% | 6% | 41 | Search C+CBL | Search C+CBL |
5 | SLAP 2 | 6 | 80% | 1% | 4 | Search SLAP+2 | Search SLAP+2 |
6 | CBL PROTEINS | 6 | 71% | 1% | 5 | Search CBL+PROTEINS | Search CBL+PROTEINS |
7 | CBL FAMILY | 6 | 100% | 1% | 4 | Search CBL+FAMILY | Search CBL+FAMILY |
8 | TULA | 5 | 63% | 1% | 5 | Search TULA | Search TULA |
9 | C CB1 | 4 | 75% | 0% | 3 | Search C+CB1 | Search C+CB1 |
10 | D CBL | 4 | 75% | 0% | 3 | Search D+CBL | Search D+CBL |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | V CBL | 123 | 77% | 12% | 85 |
2 | C CBL | 95 | 33% | 35% | 240 |
3 | PROTOONCOGENE C CBL | 51 | 69% | 6% | 44 |
4 | CIN85 | 24 | 68% | 3% | 21 |
5 | INTEGRIN SIGNALING PATHWAY | 23 | 74% | 2% | 17 |
6 | STS 1 | 15 | 88% | 1% | 7 |
7 | EGF STIMULATION | 14 | 64% | 2% | 14 |
8 | CBL DEPENDENT MANNER | 14 | 100% | 1% | 7 |
9 | MEDIATED NEGATIVE REGULATION | 12 | 75% | 1% | 9 |
10 | MUTATED C CBL | 9 | 83% | 1% | 5 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Cbl: Many adaptations to regulate protein tyrosine kinases | 2001 | 397 | 106 | 75% |
Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases | 2013 | 24 | 206 | 51% |
The Cbl interactome and its functions | 2005 | 210 | 121 | 59% |
The Cbl family proteins: Ring leaders in regulation of cell signaling | 2006 | 150 | 310 | 54% |
RTK SLAP DOWN: The emerging role of Src-like adaptor protein as a key player in receptor tyrosine kinase signaling | 2015 | 1 | 70 | 44% |
Cbl and Human Myeloid Neoplasms: The Cbl Oncogene Comes of Age | 2010 | 49 | 28 | 61% |
c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses | 2005 | 120 | 140 | 60% |
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis | 2011 | 109 | 185 | 14% |
Negative regulation of PTK signalling by Cbl proteins | 2005 | 44 | 50 | 80% |
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis | 2013 | 12 | 131 | 35% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | NEIL BOGART MEM S | 7 | 67% | 0.9% | 6 |
2 | BACTERIAL INFECT IMMUN | 4 | 67% | 0.6% | 4 |
3 | MEDLYMPHOCYTE BIOL SECT | 3 | 42% | 0.7% | 5 |
4 | HEMATOL ONCOL MS 57 | 1 | 100% | 0.3% | 2 |
5 | NOVO NORDISK PHARMACHUO KU | 1 | 100% | 0.3% | 2 |
6 | OFF THER EUT REVIEW BIOL EVALUAT | 1 | 40% | 0.3% | 2 |
7 | MED RHEUMATOL IMMUNOL ALLERGY | 1 | 10% | 1.2% | 8 |
8 | HEMATOL HEMATOL MALIGNANCY | 1 | 33% | 0.3% | 2 |
9 | SREE BALAJI MED DENT HOSP | 1 | 33% | 0.3% | 2 |
10 | UJF UMR 5075 | 1 | 33% | 0.3% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000190101 | SECRETION INHIBITION//RNF13//PROTEASE ASSOCIATED DOMAIN |
2 | 0.0000152804 | SLP 76//LINKER FOR ACTIVATION OF T CELLS//SECT LYMPHOCYTE SIGNALING |
3 | 0.0000145321 | SYK//SPLEEN TYROSINE KINASE//R788 |
4 | 0.0000136671 | NEDD9//HEF1//CRK |
5 | 0.0000128048 | SPROUTY//SPRED//SPROUTY 2 |
6 | 0.0000125446 | ESCRT//ALG 2//TSG101 |
7 | 0.0000112483 | VAV//VAV1//VAV3 |
8 | 0.0000099302 | GRB7//GRB14//GRB10 |
9 | 0.0000080327 | DSK2//UBIQUILIN 1//LUBAC |
10 | 0.0000078031 | GRB2//SH2 DOMAIN//SH3 DOMAIN |